Who
James Parker Brady
Chief Human Resources Officer
Company insider
Files Form 4 as: Chief Human Resources Officer, Ardelyx.
In numbers
- Trades disclosed
- 14
- Buys
- 0
- Sells
- 3
- Bought
- $0
- Sold
- $170K
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 23 Jan 2026
- Last trade
- 21 Aug 2026
- Last filed
- 25 Aug 2026
Companies traded
Activity over time
1 Feb – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 21 Aug 2026filed 25 Aug 2026 | ARDX ArdelyxBiotechnology | SEC FORM 4 Sold | $7,6211,976 at $3.86 | filing |
| 21 Aug 2026filed 25 Aug 2026 | ARDX ArdelyxBiotechnology | SEC FORM 4 Sold | $51K13,160 at $3.86 | filing |
| 21 Aug 2026filed 25 Aug 2026 | ARDX ArdelyxBiotechnology | SEC FORM 4 Sold | $7,6271,976 at $3.86 | filing |
| 21 Aug 2026filed 25 Aug 2026 | ARDX ArdelyxBiotechnology | SEC FORM 4 Sold | $51K13,160 at $3.86 | filing |
| 21 May 2026filed 22 May 2026 | ARDX ArdelyxBiotechnology | SEC FORM 4 Sold | $12K1,846 at $6.27 | filing |
| 21 May 2026filed 22 May 2026 | ARDX ArdelyxBiotechnology | SEC FORM 4 Sold | $12K1,846 at $6.27 | filing |
| 20 Feb 2026filed 23 Feb 2026 | ARDX ArdelyxBiotechnology | SEC FORM 4 Sold | $13K2,234 at $5.87 | filing |
| 20 Feb 2026filed 23 Feb 2026 | ARDX ArdelyxBiotechnology | SEC FORM 4 Sold | $1,766309 at $5.71 | filing |
| 20 Feb 2026filed 23 Feb 2026 | ARDX ArdelyxBiotechnology | SEC FORM 4 Sold | $13K2,234 at $5.87 | filing |
| 20 Feb 2026filed 23 Feb 2026 | ARDX ArdelyxBiotechnology | SEC FORM 4 Sold | $1,764309 at $5.71 | filing |
| 23 Jan 2026filed 26 Jan 2026 | ARDX ArdelyxBiotechnology | SEC FORM 4 Code A | —99,455 at $0.00 | filing |
| 23 Jan 2026filed 26 Jan 2026 | ARDX Ardelyxoption or derivative · Biotechnology | SEC FORM 4 Code A | —149,185 at $0.00 | filing |
| 23 Jan 2026filed 26 Jan 2026 | ARDX Ardelyxoption or derivative · Biotechnology | SEC FORM 4 Code A | —149,185 at $0.00 | filing |
| 23 Jan 2026filed 26 Jan 2026 | ARDX ArdelyxBiotechnology | SEC FORM 4 Code A | —99,455 at $0.00 | filing |
News
Pomerantz LLP Issues Important Reminder to Investors in Ardelyx, Inc. ...ARDX · pr-inside.com · 25 Oct 2026Ardelyx Presents Real-World Data at ASN Kidney Week 2026 Showing Serum Phosphate Reductions Following XPHOZAH® (tenapanor) Initiation With or Without Phosphate BindersARDX · manilatimes.net · 23 Oct 2026November 16, 2026 Deadline: Join Class Action Lawsuit Against Ardelyx, ...ARDX · pr-inside.com · 20 Oct 2026
0 headlines in the last 90 days name James Parker Brady; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.